

Silco Pharmaceuticals Limited
Un-Audited Third Quarter Financial Statements
For the Period Ended March 31, 2023

Silco Pharmaceuticals Limited
Statement of Financial Position (Un-Audited)
As at March 31, 2023

Particulars	Notes	Amount in Taka	
		31 March 2023	30 June 2022
Assets			
Non Current Assets		1,764,791,636	1,670,995,957
Property, Plant and Equipment	3.00	1,609,877,823	1,469,803,663
Right of Use Assets	4.00	952,467	3,809,870
Capital Work-in-Progress	5.00	153,961,347	197,382,425
Current Assets		998,028,471	1,048,739,867
Inventories	6.00	455,824,111	457,839,504
Trade and Other Receivables	7.00	369,048,027	389,236,460
Advances, Deposits and Prepayments	8.00	130,673,995	137,038,345
Cash and Cash Equivalents	9.00	26,656,793	26,719,260
Investment In Share	10.00	15,825,546	37,906,298
Total Assets		2,762,820,108	2,719,735,824
Shareholders Equity and Liabilities			
Shareholders Equity		2,313,838,667	2,278,623,335
Share Capital	11.00	1,038,070,000	1,038,070,000
Unrealized Gain/Loss on Marketable Securities		(10,824,466)	(10,687,292)
Retained Earnings	12.00	1,286,593,133	1,251,240,627
Non-Current Liabilities		158,411,043	150,207,253
Lease Liabilities (Non Current Portion)			
Deferred Tax Liabilities	13.00	158,411,043	150,207,253
Current Liabilities		290,570,399	290,905,236
Trade and Other Payable	14.00	8,021,750	12,334,060
Lease Liabilities (Current Portion)	15.00	1,061,563	4,112,546
Payable to IPO Applicants		184,607	184,728
Provision for Expenses	16.00	7,867,343	6,996,585
Liabilities for contribution to WPPF	17.00	4,330,072	9,929,514
Dividend Payables (Unclaimed)	18.00	2,618,447	2,142,006
Provision for income tax	19.00	266,486,617	255,205,797
Total Shareholders Equity and Liabilities		2,762,820,108	2,719,735,824
Net Asset Value (NAV) per Share	27.00	22.29	21.95

The annexed notes form an integral part of these financial statements.



Chairman Managing Director Director Company Secretary Chief Financial Officer

SIGNED IN TERMS OF OUR ANNEXED REPORT OF EVEN DATE

Date: 30 April 2023
Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income (Un-Audited)
For the period ended March 31, 2023

Particulars	Notes	Amount in Taka			
		01 July 2022 to 31 Mar. 2023	01 July 2021 to 31 Mar. 2022	01 Jan. 2023 to 31 Mar. 2023	01 Jan. 2022 to 31 Mar. 2022
Turnover	20.00	359,863,947	500,864,767	124,228,048	179,853,256
Less: Cost of Goods Sold	21.00	232,167,729	329,319,981	76,597,869	112,153,805
Gross Profit/(Loss)		127,696,218	171,544,785	47,630,179	67,699,451
Less: Operating Expenses	22.00	59,671,125	69,623,053	19,826,953	22,565,856
Profit from Operation		68,025,093	101,921,733	27,803,225	45,133,595
Less: Financial Expenses	23.00	84,479	214,477	26,701	61,083
Less: Financial Expenses (Lease)		179,676	431,347	37,927	123,629
Non-operation Income	24.00	23,170,564	11,133,223	1,639,035	2,172,876
Profit before Contribution to WPPF		90,931,502	112,409,132	29,377,632	47,121,759
Less: Workers' Profit Participation/Welfare Fund (WPPF)		4,330,072	5,352,816	1,398,935	2,243,893
Profit before Income Tax		86,601,430	107,056,316	27,978,698	44,877,866
Less: Provision for Income Tax	25.00	19,484,610	23,911,841	6,294,495	10,604,886
Current Tax		11,280,820	20,184,586	2,774,154	8,924,654
Deferred Tax		8,203,790	3,727,255	3,520,342	1,680,232
Net Profit after Tax (Transferred to CE)		67,116,820	83,144,475	21,684,202	34,272,980
Other Comprehensive Income:					
Unrealized Gain/Loss on Investment		(137,174)	(6,127,192)	4,184,349	1,143,506
Total Comprehensive income		66,979,646	77,017,283	25,868,551	35,416,487
Earnings per Share (EPS)	26.00	0.65	0.80	0.21	0.33

The annexed notes form an integral part of these financial statements.

মাহিনা জাহাঙ্গীর
Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: 30 April 2023

Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Changes in Equity (Un-Audited)
For the period ended March 31, 2023

Amount in Taka


Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2022	1,038,070,000	(10,687,292)	1,251,240,627	2,278,623,335
Net Profit/(Loss) during the period	-	-	67,116,820	67,116,820
Declared 5% Cash Dividend			(31,764,315)	(31,764,315)
Unrealized Gain/Loss on Marketable Shares	-	(137,174)	-	(137,174)
Balance as on March 31, 2023	1,038,070,000	(10,824,466)	1,286,593,133	2,313,838,667

Statement of Changes in Equity
For the period ended March 31, 2022

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2021	1,038,070,000	(369,919)	1,230,318,041	2,268,018,123
Net Profit/(Loss) during the period	-	-	83,144,475	83,144,475
Declared 10% Cash Dividend			(63,528,630)	(63,528,630)
Unrealized Gain/Loss on Marketable Shares	-	(6,127,192)	-	(6,127,192)
Balance as on March 31, 2022	1,038,070,000	(6,497,110)	1,249,933,886	2,281,506,776


Chairman


Managing Director


Director


Company Secretary


Chief Financial Officer

Date: 30 April 2023
Place: Dhaka

Silco Pharmaceuticals Limited

Statement of Cash Flows (Un-Audited)

For the period ended March 31, 2023

Particulars	Notes	Amount in Taka	
		01 July 2022 to 31 Mar. 2023	01 July 2021 to 31 Mar. 2022
A. Cash Flows from Operating Activities			
Cash received from Customers	31.00	380,052,381	488,321,850
Cash received from Non-operating income		3,864,322	4,657,209
Cash Paid to Suppliers	32.00	(129,006,346)	(234,485,772)
Cash Paid to Employees	33.00	(48,625,643)	(56,727,505)
Cash Paid to Others	34.00	(46,051,709)	(57,909,872)
Financial Expenses		(84,479)	(214,477)
Income Tax Paid		(5,992,895)	(7,829,591)
Net cash flows from operating activities		154,155,630	135,811,841
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		(2,980,960)	(25,919,228)
Cash Received/Payments to/from FDR			-
Cash Payments for Capital Work-in-Progress		(157,968,304)	(14,584,110)
Gain on Investment		19,306,242	6,476,014
Investment in Share		21,943,578	(28,813,235)
Net cash used in investing activities		(119,699,444)	(62,840,558)
C. Cash Flows from Financing Activities			
Refund to IPO Applicants		(121)	(293)
Financial Expenses (Lease)		(179,676)	(431,347)
Principle payment (Lease)		(3,050,982)	(2,799,311)
Cash dividend paid		(31,287,875)	(62,465,298)
Net Cash used for financing activities		(34,518,653)	(65,696,249)
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		(62,467)	7,275,034
E. Cash and Cash Equivalents at the beginning of the year		26,719,260	53,031,144
F. Cash and Cash Equivalents at the end of the period (D+E)		26,656,793	60,306,178
Net Operating Cash Flows Per Share (NOCFPS)	28.00	1.49	1.31

নাস্তুর জাহাঙ্গীর
Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: 30 April 2023

Place: Dhaka